PT  - JOURNAL ARTICLE
AU  - Alexandra Hunter
AU  - Michael Williams
TI  - Long-term outcomes for patients treated for macular oedema secondary to retinal vein occlusion: a systematic review
AID  - 10.1136/bmjophth-2022-001010
DP  - 2022 Jun 01
TA  - BMJ Open Ophthalmology
PG  - e001010
VI  - 7
IP  - 1
4099  - http://bmjophth.bmj.com/content/7/1/e001010.short
4100  - http://bmjophth.bmj.com/content/7/1/e001010.full
SO  - BMJ Open Ophth2022 Jun 01; 7
AB  - This systematic review assessed the long-term outcomes for patients treated with intravitreal antivascular endothelial growth factor or dexamethasone for macular oedema (MO) secondary to retinal vein occlusion (RVO). Studies investigating patients of all ages with MO due to RVO only were included. The review was deliberately broad in scope, including comparative and non-comparative studies to ensure inclusion of real-world type evidence. Risk of bias was assessed. In total, 76 data sets were included (10 775 participants). Overall, mean best-corrected visual acuity (BCVA) improved from baseline to 5 years by 16.1 letters (p<0.01). BCVA improved from baseline in both central RVO (CRVO) and branch RVO (BRVOs) at 2 years, by 9.1 (p<0.01) (difference from baseline in CRVOs) and 9.1 (p<0.01) letters, respectively. At 5 years, BCVA improved from baseline in CRVOs by 15.6 letters and in BRVOs by 16.2; the difference between RVO types was not significant (p=0.18). Two studies had 5-year data for ranibizumab, and improvement was evident. There was no significant difference between outcomes in randomised controlled trials (RCTs) compared with non RCTs. These results suggest a benefit to receiving long-term intravitreal treatments for MO due to RVO.